Roche se asegura un fármaco contra la obesidad de zealand por hasta 5.300 millones de dólares
ZÚRICH, 12 mar (Reuters) - Roche adquirió los derechos de una terapia contra la obesidad de la danesa Zealand Pharma en un ...
Nuevo fármaco contra obesidad busca competir con Ozempic
Un acuerdo entre el gigante farmacéutico Roche y la danesa Zealand Pharma busca impulsar el desarrollo de este medicamento.
Endocrinology Advisor11h
GLP-1 Drugs Associated With a Reduced Risk of Multiple Age-Related Ocular Diseases
Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.
Healio20h
GLP-1 agonists may be protective against hip fracture in patients with type 2 diabetes
GLP-1 agonists may be protective against hip fracture when administered for the treatment of type 2 diabetes, according to ...
Compound versions of weight loss drugs will no longer be available, FDA rules
The FDA says state-licensed compounding pharmacies must immediately stop making compound versions of GLP-1 drugs. Larger, national licensed facilities making compound versions of Zepbound have until ...
WISH-TV on MSN4h
Older adults face health risks from GLP-1 weight loss medications
Weight loss medications such as Wegovy and Zepbound can be effective for quick results and health benefits, but older adults ...
The Truth About GLP-1s and Your Health
GLP-1 medications are making headlines in medical weight loss—learn how they impact overall health and chronic disease ...